Arvinas Inc. Common Stock (ARVN)
Stock · NASDAQ · Health Care
$6.96as of 10/16/2026
Price chart
Active signals
ARVN Signal Track Record
How signals performed across all stocks →What ARVN's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 33 | -2.9% | 45% | September 14, 2026 |
| Bollinger Band Breakdown | 24 | -8.1% | 46% | September 10, 2026 |
| Bollinger Band Breakout | 21 | -9.6% | 38% | August 19, 2026 |
| 200-Day Moving Average TouchActive now | 7 | -12.7% | 43% | April 23, 2026 |
| Any 20-session window (baseline) | -2.2% | 44% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ARVN
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 246
- Website
- www.arvinas.com/
Fundamentals
- 1-day range
- $6.93$7.3
- Market cap
- $567.55M
- P/E (trailing)
- 50.48
- P/E (forward)
- -2.16
- EPS (trailing)
- $0.16
- Dividend yield
- —
- Beta
- 1.81
- Avg. volume
- 800.9K
How Arvinas Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 24, 2026 · via SEC EDGAR / Finnhub
Forecasts
14 analyst ratings
Arvinas Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ARVNArvinas Inc. Common Stock$6.97▼ 2.65%Market cap $567.55MP/E 50.48$6.74$14.51
- RLMDRelmada Therapeutics Inc. Common Stock$3.1▼ 3.13%Market cap $563.26MP/E —$1.8$8
- CTNMContineum Therapeutics Inc. Class A Common Stock$7.08▼ 10.38%Market cap $577.48MP/E —$7.96$17.79
- SPRYARS Pharmaceuticals Inc. Common Stock$4.02▼ 1.23%Market cap $551.13MP/E —$3.89$13.15
- ALTAltimmune Inc. Common Stock$2.2▼ 6.78%Market cap $585.37MP/E —$2.56$6.44
- STTKShattuck Labs Inc. Common Stock$5.42▼ 1.99%Market cap $549.03MP/E —$1.7$8.33
- SLNSilence Therapeutics Plc American Depository Share$8.68▼ 7.17%Market cap $548.50MP/E —$1.06$5.99
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ARVN Arvinas Inc. Common Stock | $567.55M | 50.48 | $6.97 | ▼ 2.65% | $6.74$14.51 |
| RLMD Relmada Therapeutics Inc. Common Stock | $563.26M | — | $3.1 | ▼ 3.13% | $1.8$8 |
| CTNM Contineum Therapeutics Inc. Class A Common Stock | $577.48M | — | $7.08 | ▼ 10.38% | $7.96$17.79 |
| SPRY ARS Pharmaceuticals Inc. Common Stock | $551.13M | — | $4.02 | ▼ 1.23% | $3.89$13.15 |
| ALT Altimmune Inc. Common Stock | $585.37M | — | $2.2 | ▼ 6.78% | $2.56$6.44 |
| STTK Shattuck Labs Inc. Common Stock | $549.03M | — | $5.42 | ▼ 1.99% | $1.7$8.33 |
| SLN Silence Therapeutics Plc American Depository Share | $548.50M | — | $8.68 | ▼ 7.17% | $1.06$5.99 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Arvinas Says ARV-102 Shows Dose-Dependent Eye Movement Improvement In 24-Patient Phase 1 Parkinson's Trial Not Designed To Assess Efficacybenzinga · 10/7/2026
- Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s DiseaseYahoo · 10/7/2026
- Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders®Yahoo · 10/1/2026
- Arvinas To Present Biomarker Data From Phase 1 Clinical Trial Of ARV-102 In Participants With Parkinson’s Disease At 2026 International Congress Of Parkinson’s Disease And Movement DisordersBenzinga · 10/1/2026
- Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Yahoo · 9/29/2026
- Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology CandidateYahoo · 9/28/2026
- Arvinas Q2 2026 Earnings Call TranscriptBenzinga · 9/25/2026
- Ginkgo Bioworks (DNA) Surges 11.1%: Is This an Indication of Further Gains?Yahoo · 9/18/2026
- Arvinas, Inc. (ARVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeekingAlpha · 9/16/2026
Insider Activity
Insider Actions →- Kennedy Edward Moore Jr. · June 24, 2026 · Grant22.7K
- Kennedy Edward Moore Jr. · June 24, 2026 · Grant15.5K
- Morrison Briggs · June 24, 2026 · Grant22.7K
- Morrison Briggs · June 24, 2026 · Grant15.5K
- Smaldone Alsup Laurie · June 24, 2026 · Grant22.7K
- Smaldone Alsup Laurie · June 24, 2026 · Grant15.5K
- Bain Linda · June 24, 2026 · Grant22.7K
- Bain Linda · June 24, 2026 · Grant15.5K
- Cunningham Everett · June 24, 2026 · Grant22.7K
- Cunningham Everett · June 24, 2026 · Grant15.5K
- Leslie Norwalk V · June 24, 2026 · Grant22.7K
- Leslie Norwalk V · June 24, 2026 · Grant15.5K
- Saik Andrew · June 24, 2026 · Sale5.7K @ $8.16
- Cacace Angela M · June 17, 2026 · Sale2.6K @ $7.6
- Teel Randy · May 21, 2026 · Sale2.2K @ $9.04
Institutional Ownership
March 31, 2026
- Total shares held
- 49.57M
- Total value held
- $502.06M
- Institutional holders
- 199
- Unknown6.80M
- Unknown3.64M
- Unknown3.46M
- Unknown2.69M
- Unknown2.39M
- Unknown1.98M
- Unknown1.83M
- Unknown1.83M
- Unknown1.56M
- Unknown1.44M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Arvinas Releases Q2 2026 Earnings Call Transcript
Arvinas has published the transcript of its Q2 2026 earnings call. The document contains the company's financial results, guidance, and management commentary. Investors can use the transcript to assess the company's recent performance and future outlook.
Arvinas Releases Q2 2026 Earnings Call Transcript. Arvinas has published the transcript of its Q2 2026 earnings call. The document contains the company's financial results, guidance, and management commentary. Investors can use the transcript to assess the company's recent performance and future outlook.